Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study
Psychiatry and Clinical Neurosciences · 2026-09 · 80 (9) · 740-747
DOI: 10.1111/pcn.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 20.05.2026. Verfasst von Aran Tajika und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion and Behavioral Sciences, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Patient Preference, Nootropic Agents, Public Opinion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method.
Methods
We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated risks and high cost. We calculated SWD as the minimum required increase in the possibility of maintaining cognitive function (relative to the 50% without lecanemab) that patients would accept in exchange for the burdens of treatment (adverse effects, costs, other inconveniences). We examined the median SWD for two scenarios: a family member (SWD‐families) and others (SWD‐others), and analyzed subgroup differences.
Results
The median SWD revealed a 15% increase for SWD‐families and SWD‐others. This value exceeds the drug's actual efficacy of an 8% increase. Notably, 17% of respondents reported zero SWD, driven by an intense fear of AD and possibly high expectations from media coverage. Including these participants, nearly half of the respondents considered the current effect worthwhile. No noticeable difference was found between the SWD‐families and SWD‐others.
Conclusion
Based on Japanese clinical scenarios, the public's median expectation for lecanemab exceeds its efficacy, though its current benefit remains acceptable to nearly half the population. These findings underscore that the SWD is shaped by psychological drivers, including fear and hope, rather than just reasoned evaluation. Clinicians must manage these expectations, accounting for highly heterogeneous treatment preferences. Future research should account for emotional factors that can overshadow a rational assessment of treatment value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Promotion and Behavioral Sciences, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
- Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima, Japan.
- Population Health and Policy Research Unit, Center for Medical Education and Internationalization, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Next-Generation Organ Transplantation, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
- Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
ORCID-Profile: Aran Tajika, Kenji Omae, Ethan Sahker, Yan Luo, Yoshiteru Takekita, Toshi A Furukawa
Zitieren
APA
Tajika, A., Omae, K., Sahker, E., Luo, Y., Takekita, Y., & Furukawa, T. A. (2026). Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study. Psychiatry and Clinical Neurosciences, 80(9), 740-747. https://doi.org/10.1111/pcn.70082
Vancouver
Tajika A, Omae K, Sahker E, Luo Y, Takekita Y, Furukawa TA. Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study. Psychiatry and Clinical Neurosciences. 2026;80(9):740-747. doi:10.1111/pcn.70082
BibTeX
@article{Tajika2026,
author = {Tajika, Aran and Omae, Kenji and Sahker, Ethan and Luo, Yan and Takekita, Yoshiteru and Furukawa, Toshi A},
title = {Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study},
journal = {Psychiatry and Clinical Neurosciences},
year = {2026},
volume = {80},
number = {9},
pages = {740--747},
doi = {10.1111/pcn.70082}
}
EUVIMED